P-MUC1C-ALLO1

N/A

Report date: 2022/01/17 12:14:22

Base Information

Drug NameP-MUC1C-ALLO1

Drug Alias NameP-MUC1C-101P-MUC1C-ALLO1

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionMucin-1 inhibitors

TargetsMucin-1

Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungNasopharyngeal Neoplasms +[10]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesPoseida Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesAstellas Pharma Inc Poseida Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungNasopharyngeal Neoplasms +[10]

Inactive IndicationsN/A

Other Information

ATC CodeN/A